Analyst Scoreboard: 7 Ratings For RxSight
Portfolio Pulse from Benzinga Insights
In the past three months, 7 analysts have rated RxSight (NASDAQ:RXST), with 5 bullish and 2 somewhat bullish ratings. The average 12-month price target is $63.14, down from $67.50. Analysts have adjusted their ratings and price targets, reflecting changing market conditions and company performance. RxSight, a medical technology company, has shown significant revenue growth but faces challenges in asset utilization.
October 29, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RxSight has received 7 analyst ratings, mostly bullish, with an average price target of $63.14, down from $67.50. Analysts have adjusted ratings and targets, reflecting market conditions and company performance. The company shows strong revenue growth but faces challenges in asset utilization.
The news provides a comprehensive overview of analyst ratings for RxSight, showing a generally positive sentiment with a slight decrease in the average price target. The company's strong revenue growth is a positive indicator, but challenges in asset utilization may offset this. The mixed signals suggest a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100